Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer

EMBO Journal

Volumn 34, Issue 4, 2015, Pages 502-516

  Chen, Zhong ^a   Lan, Xun ^a   Thomas Ahner, Jennifer M ^a   Wu, Dayong ^a   Liu, Xiangtao ^a   Ye, Zhenqing ^a,b   Wang, Liguo ^c   Sunkel, Benjamin ^a   Grenade, Cassandra ^a   Chen, Junsheng ^c   Zynger, Debra L ^a   Yan, Pearlly S ^a   Huang, Jiaoti ^d   Nephew, Kenneth P ^e   Huang, Tim H M ^b   Lin, Shili ^f   Clinton, Steven K ^a   Li, Wei ^c   Jin, Victor X ^a,b   Wang, Qianben ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b San Antonio Cancer Institute   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

Androgen receptor; ChIP exo; DNA motif switching; Prostate cancer; Transcription factor

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR BINDING ELEMENT; BICALUTAMIDE; BINDING PROTEIN; DEOXYRIBONUCLEASE I; ENZALUTAMIDE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANDROGEN; ANDROGEN RECEPTOR ANTAGONIST; AR PROTEIN, HUMAN; DNA;

ARTICLE; BINDING AFFINITY; CANCER RISK; CARCINOGENESIS; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA SEQUENCE; DNA STRUCTURE; ENHANCER REGION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; LNCAP CELL LINE; MALE; NUCLEOSOME; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN MOTIF; REPORTER GENE; RNA INTERFERENCE; TRANSCRIPTION REGULATION; CELL PROLIFERATION; CHEMISTRY; GEL MOBILITY SHIFT ASSAY; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84923062755     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.15252/embj.201490306     Document Type: Article

References (47)

1. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155: 1309-1322
2. Augello MA, Hickey TE, Knudsen KE (2011) FOXA1: master of steroid receptor function in cancer. EMBO J 30: 3885-3894
3. Badis G, Berger MF, Philippakis AA, Talukder S, Gehrke AR, Jaeger SA, Chan ET, Metzler G, Vedenko A, Chen X, Kuznetsov H, Wang CF, Coburn D, Newburger DE, Morris Q, Hughes TR, Bulyk ML (2009) Diversity and complexity in DNA recognition by transcription factors. Science 324: 1720-1723
4. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL (2013) Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2: e00499
5. Burd CJ, Ward JM, Crusselle-Davis VJ, Kissling GE, Phadke D, Shah RR, Archer TK (2012) Analysis of chromatin dynamics during glucocorticoid receptor activation. Mol Cell Biol 32: 1805-1817
6. Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F (2008) Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature 456: 350-356
7. Chandra V, Huang P, Potluri N, Wu D, Kim Y, Rastinejad F (2013) Multidomain integration in the structure of the HNF-4alpha nuclear receptor complex. Nature 495: 394-398
8. Chen Z, Wang L, Wang Q, Li W (2010) Histone modifications and chromatin organization in prostate cancer. Epigenomics 2: 551-560
9. Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, Wang Q (2011) Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J 30: 2405-2419
10. D' Ambrogio A, Nagaoka K, Richter JD (2013) Translational control of cell growth and malignancy by the CPEBs. Nat Rev Cancer 13: 283-290
11. Denayer S, Helsen C, Thorrez L, Haelens A, Claessens F (2010) The rules of DNA recognition by the androgen receptor. Mol Endocrinol 24: 898-913
12. Furey TS (2012) ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions. Nat Rev Genet 13: 840-852
13. Guerrero J, Alfaro IE, Gomez F, Protter AA, Bernales S (2013) Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate 73: 1291-1305
14. Hardison RC, Taylor J (2012) Genomic approaches towards finding cis-regulatory modules in animals. Nat Rev Genet 13: 469-483
15. He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q, Zhang Y, Xu K, Ni M, Lupien M, Mieczkowski P, Lieb JD, Zhao K, Brown M, Liu XS (2010) Nucleosome dynamics define transcriptional enhancers. Nat Genet 42: 343-347
16. He HH, Meyer CA, Chen MW, Jordan VC, Brown M, Liu XS (2012) Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res 22: 1015-1025
17. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276-308
18. Helsen C, Dubois V, Verfaillie A, Young J, Trekels M, Vancraenenbroeck R, De Maeyer M, Claessens F (2012a) Evidence for DNA-binding domain-ligand-binding domain communications in the androgen receptor. Mol Cell Biol 32: 3033-3043
19. Helsen C, Kerkhofs S, Clinckemalie L, Spans L, Laurent M, Boonen S, Vanderschueren D, Claessens F (2012b) Structural basis for nuclear hormone receptor DNA binding. Mol Cell Endocrinol 348: 411-417
20. Helsen C, Claessens F (2014) Looking at nuclear receptors from a new angle. Mol Cell Endocrinol 382: 97-106
21. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43: 27-33
22. John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, Johnson TA, Hager GL, Stamatoyannopoulos JA (2011) Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet 43: 264-268
23. Jolma A, Yan J, Whitington T, Toivonen J, Nitta KR, Rastas P, Morgunova E, Enge M, Taipale M, Wei G, Palin K, Vaquerizas JM, Vincentelli R, Luscombe NM, Hughes TR, Lemaire P, Ukkonen E, Kivioja T, Taipale J (2013) DNA-binding specificities of human transcription factors. Cell 152: 327-339
24. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B, Hager JH (2013) A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 3: 1020-1029
25. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, Yuan J, Kovats SG, Kim S, Cooke VG, Monahan JE, Stegmeier F, Roberts TM, Sellers WR, Zhou W, Zhu P (2013) An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3: 1030-1043
26. Lan X, Bonneville R, Apostolos J, Wu W, Jin VX (2011) W-ChIPeaks: a comprehensive web application tool for processing ChIP-chip and ChIP-seq data. Bioinformatics 27: 428-430
27. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835-839
28. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK et al (2011) The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J 30: 2719-2733
29. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR (2009) DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324: 407-410
30. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123: 2948-2960
31. Rhee HS, Pugh BF (2011) Comprehensive genome-wide protein-DNA interactions detected at single-nucleotide resolution. Cell 147: 1408-1419
32. Rhee HS, Pugh BF (2012) Genome-wide structure and organization of eukaryotic pre-initiation complexes. Nature 483: 295-301
33. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481: 389-393
34. Serandour AA, Brown GD, Cohen JD, Carroll JS (2013) Development of an Illumina-based ChIP-exonuclease method provides insight into FoxA1-DNA binding properties. Genome Biol 14: R147
35. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, Neal DE (2013) The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23: 35-47
36. Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24: 1967-2000
37. Thomas-Chollier M, Watson LC, Cooper SB, Pufall MA, Liu JS, Borzym K, Vingron M, Yamamoto KR, Meijsing SH (2013) A naturally occurring insertion of a single amino acid rewires transcriptional regulation by glucocorticoid receptor isoforms. Proc Natl Acad Sci USA 110: 17826-17831
38. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790
39. Tsai SY, Carlstedt-Duke J, Weigel NL, Dahlman K, Gustafsson JA, Tsai MJ, O'Malley BW (1988) Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell 55: 361-369
40. Wang Q, Udayakumar TS, Vasaitis TS, Brodie AM, Fondell JD (2004) Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells. J Biol Chem 279: 17319-17328
41. Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M (2007) A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 27: 380-392
42. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG (2009) ChIP-seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 28: 1418-1428
43. Wu D, Zhang C, Shen Y, Nephew KP, Wang Q (2011) Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab 22: 474-480
44. Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, Grenade C, Ke J, Zhang C, Chen H, Nephew KP, Huang TH, Liu Z, Jin VX, Wang Q (2014) Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res 42: 3607-3622
45. Xu Y, Chen SY, Ross KN, Balk SP (2006) Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res 66: 7783-7792
46. Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Wang Y, Busby SA, Pascal BD, Garcia-Ordonez RD, Bruning JB, Istrate MA, Kojetin DJ, Dodge JA, Burris TP, Griffin PR (2011) DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat Struct Mol Biol 18: 556-563
47. Zhao Y, Stormo GD (2011) Quantitative analysis demonstrates most transcription factors require only simple models of specificity. Nat Biotechnol 29: 480-483